Marco Meglio, Assistant Managing Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at mmeglio@neurologylive.com
Tiziana Life Sciences Plans IND for Phase 1 Study of Intranasal Foralumab in Alzheimer Disease
October 25th 2022Foralumab, an anti-CD3 monoclonal antibody, has been previously assessed in diseases such as progressive multiple sclerosis and Crohn disease, as well as in patients with mild to moderate COVID-19.
Epilepsy Rates in Hypertension Lowered Among Those on Angiotensin Receptor Blocker Therapy
October 24th 2022Within 5 years after the index date, the lowest proportion of epilepsy diagnoses were among those treated with angiotensin receptor blockers and highest in those on ß-blockers and calcium channel blockers.
Composite Speech Score Detects Longitudinal Cognitive Changes Better Than Some Traditional Measures
October 22nd 2022The composite score, which consisted of 6 linguistic features and 3 acoustic features, was shown to be sensitive to measures of disease progression, with a potential to help understand treatment response.
Deutetrabenazine Tablets Show Long-term Safety, Efficacy as Huntington Disease Chorea Treatment
October 21st 2022For patients who rolled over to the ARC-HD extension study from the previous First-HD trial, there was a 4.5-point reduction in mean chorea scores at week 8 that were maintained through week 145.
Clinician-Based Survey Highlights Challenges in Diagnosing Narcolepsy in Children, Adolescents
October 20th 2022When asked which efficacious diagnostic or treatment options they hope to see in the future, a majority of physicians, especially specialists, expressed a desire to see more useful biomarkers, followed by more effective diagnostic tests overall.
Fewer Poststroke Functional Improvement Seen in EVT-Treated Patients With Lower ASPECTS Scores
October 19th 2022More than 40% of patients with ASPECTS scores between 4 and 5 treated with EVT showed functional outcome improvements, whereas slightly over 20% of those with scores between 0 to 3 demonstrated the same.